AnGes
4563.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Operating income | −¥4.4bn | −¥4.9bn | −¥4.8bn | −¥9.7bn | −¥10.0bn | — |
| Ordinary income | −¥4.5bn | −¥3.1bn | ¥2.0bn | −¥8.0bn | −¥7.9bn | −¥5.3bn |
| Total assets | ¥4.4bn | ¥3.7bn | ¥38.7bn | ¥40.7bn | ¥44.9bn | ¥34.1bn |
| Net assets / equity | ¥2.7bn | ¥2.4bn | ¥37.3bn | ¥34.1bn | ¥38.7bn | ¥29.4bn |
| EPS (basic) | ¥-15.95 | ¥-167.03 | ¥5.64 | ¥-52 | ¥-54.91 | ¥-44.63 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 62 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 170 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 170 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 170 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 64 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 168 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3Amended | 40 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 64 figures · EDINET |
24 more reports are still being processed.